[straight news network Beijing on March 23 news] (Guangming) in the just concluded two sessions, Li Bin, director of the Planning Commission said: already have, including imports of anticancer drugs and other five kinds of drugs in the Planning Commission of negotiation mechanism, the price of up to 50%. Both of these five drugs have a significant therapeutic effect, but the price is very expensive.

Not only is a cure, since the rehabilitation of medical reform, the drug price has been at the core of the link, the measures of foreign pharmaceutical companies quite a shock. In the last year in Hunan and Zhejiang provinces of drug bidding and purchasing, it appeared that the large number of foreign pharmaceutical companies because the tender price is too low and give up the tender of the event.

So, for this round of decline of up to 50% of the "special" negotiations, foreign pharmaceutical companies will choose to accept the proposal, with lower prices in exchange for greater market?? "daily of the first finance and economics" reporter in an interview with the digital foreign senior pharmaceutical companies has been affirmative answer.

"If the price of drugs has a certain adjustment in the bidding, we can accept it. As a foreign pharmaceutical companies, we must see the Chinese market if only in the generic drug competition, is unlikely to succeed. " When Myers, President of China Lin Taikang told the "First Financial Daily" the reporter said, "ten years ago we do such a decision, we expect the product slowly to out of the more common some foundation treatment in the field, or is a treatment area difference is relatively small. We want to re allocate the resources, more investment in the field of bio pharmaceutical."

In fact, for foreign pharmaceutical companies, even if prices and mature markets will not give up greater reason is from the transfer of "attention". Now foreign pharmaceutical companies for traditional drug pricing and marketing strategies were changing, in the enterprise management the most immediate impact is, the former marketing drive mode is gradually transformed into innovation driven. At present, including Bristol Squibb and Sanofi, numerous foreign pharmaceutical companies, without exception, increased investment in research and development area in China, aimed at the future development of the burden more faith in the innovative medicines.

As Lin Taikang said, it is not sustainable to rely on sophisticated products now.

Foreign pharmaceutical companies are more willing to focus on innovative medicines, mature product prices fell on the one hand, on the other hand is margin since the policy fluctuations: according to the newly issued new priority review policy, the applicant in the European Union, the United States synchronous applications and licensed to conduct clinical trials of new drug clinical trial application, or within the territory of the people's Republic of China with the same production line production and in the European Union, the United States synchronization application for listing and has passed the drug to the examination and approval authority for on-site inspection of drug registration application can be a priority review.

Despite heavy clouds of health care reform to keep the prices down, but the policy proposed again renewed foreign pharmaceutical companies in the Chinese market "possessive". Because this means simultaneous listing in China global drug has become possible, and blockbuster drugs to enter the domestic at the present stage, often need to wait for the review period of 6-8 years or even longer, this to the enterprise, is a huge time cost. After all, compared to mature drugs, new drugs, blockbuster drugs market and profit margins are more attractive.

"If we in China profit level to have further growth, very clear strategy is the drug innovation inputs must mature drug varieties of input is greater than the, because we pay more attention to China's new market reform brings us opportunities." Lin Taikang said. "The blockbuster new drug does not need to be as long as it used to be, because it is faster than ever before. In the United States, one of our patients with lung cancer is immune to cancer drugs in the market, 80% of the patients are immediately used." 3

(original title: negotiate drug prices 50%, foreign pharmaceutical companies I take that?)

Editor: Chen Feng

Interpretation of the news hot spots, showing sensitive events, more exclusive analysis, in the "things" WeChat, scan two-dimensional code free reading.